| 货号 | HY583046 |
|---|
| 产品名称 | Research Grade Satralizumab |
|---|
| 中文品名/别名 | Sapelizumab, SA-237, SA237, satralizumab-mwg, 1535963-91-7 |
|---|
| 包装规格 | 100ug / 1mg |
|---|
| 反应种属 | Human |
|---|
| 应用实验 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| 状态 | Liquid |
|---|
| 纯度 | >95% purity as determined by SDS-PAGE. |
|---|
| 储存温度 | -20℃ |
|---|
| 运输方式 | 普通冰袋 |
|---|
| 靶点 | sIL6R, Interleukin-6 receptor subunit alpha, CD126, IL-6R 1, IL-6R subunit alpha, Membrane glycoprotein 80, gp80, IL6R, IL-6RA, IL-6 receptor subunit alpha, IL-6R-alpha |
|---|
| 基因号 | P08887 |
|---|
| 宿主/表达体系 | Humanized |
|---|
| 交货期 | 现货 |
|---|
| 说明 | Satralizumab ( HY583046 ) is a research-grade recombinant antibody targeting CD126 . Produced in mammalian cells with native-like glycosylation. Highlights Research Grade — For PK/PD studies, assay development, and ADA research. Native Glycosylation — Mammalian expression ensures native-like patterns. |
|---|